Exploring the association of disease-modifying therapies for multiple sclerosis and BTK inhibitors with epilepsy
| Autor: | Afsaneh Shirani, Nil Saez-Calveras, Jack P. Antel, Moein Yaqubi, Wayne Moore, Amy L. Brewster, Olaf Stuve |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Therapeutic Advances in Neurological Disorders, Vol 17 (2024) |
| Druh dokumentu: | article |
| ISSN: | 1756-2864 17562864 |
| DOI: | 10.1177/17562864241276204 |
| Popis: | Background: Multiple lines of evidence suggest a role of inflammation in epilepsy. Seizure incidence in patients with multiple sclerosis (MS) is twofold to threefold higher than the age-matched general population. Objectives: To explore the association of MS disease-modifying therapies (DMTs) and FDA-approved Bruton tyrosine kinase inhibitors (for lymphocytic malignancies) with the occurrence of epilepsy using the US Food and Drug Administration Adverse Event Reporting System (FAERS) database. Design: Secondary analysis of the FAERS database. Methods: We conducted a disproportionality analysis of FAERS between 2003-Q4 and 2023-Q3. MS DMTs and the Bruton tyrosine kinase inhibitor, ibrutinib, were included in the analysis. An inverse association was defined by a 95% confidence interval (CI) upper limit of reporting odds ratio (ROR) |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|